Background. We report in vitro studies of a commercially available novel antimicrobial Luer-activated connector with the inner surface coated with nanoparticle-silver to prevent contaminants from forming biofilm and causing catheter-related bloodstream infection.
1 ϫ 10 were allowed to dry, and were then actuated and infused with lactated ringer's solution for 72 h, with sampling for microorganisms in downstream efferent fluid and for biofilm in the connector.
Results. Microorganisms suspended in the intraluminal fluid path of antimicrobial connectors were rapidly killed. For 5 species, there was a 5.23-6.80 mean log 10 reduction (199.999%), and with C. albicans, there was a 99.9% reduction. In clinical simulation trials, heavy contamination of downstream fluid was detected at all time points with control connectors, reaching ∼ cfu/mL at 72 h, and heavy biofilm was uniformly present; with 1 ϫ 10 the antimicrobial connectors, there was complete prevention of downstream fluid contamination and total absence of biofilm formation.
Conclusions. These simulation experiments show that needleless connectors readily acquire an internal biofilm when microorganisms gain access to the internal fluid path and that biofilm formation allows an exponential buildup of internal contamination, with shedding back into the fluid path and downstream sufficient to cause bacteremia. Incorporation of nanoparticle silver into the lining surfaces of the novel connector kills microorganisms in the fluid pathway and prevents internal biofilm formation, even with high levels of introduced contamination and continuous fluid flow. This technology deserves to be evaluated in a prospective, randomized clinical trial to determine its capacity to prevent catheter-associated bloodstream infection.
More than 500,000 intravascular device-related bloodstream infections (BSIs) occur in the United States each year, the majority caused by central venous catheters (CVCs) [1] . CVC-related BSIs are associated with prolongation of hospital stay and added costs to the health care system of $33,000-$65,000 per case [2, 3] .
Microorganisms cause CVC-related infection when they gain access to the surface of the implanted device where they can establish a biofilm [4, 5] , allowing sustained surface colonization and, ultimately, dissemination into the bloodstream. With short-term intravascular devices-peripheral intravenous catheters, arterial catheters, and noncuffed and nontunneled CVCsmost catheter-related BSIs originate from skin of the insertion site and gain access extraluminally and occasionally intraluminally [6] [7] [8] . With long-term devicescuffed and tunneled CVCs, totally implanted central venous ports, and peripherally inserted central venous catheters (PICCs)-intraluminal contaminants are the major cause of device-related BSI [9] [10] [11] [12] [13] . Needleless valved connectors for CVCs have come into near-universal use throughout the United States as part of the national movement to reduce the risk to health care workers of biohazardous sharps injuries and exposure to bloodborne viruses, such as human immunodeficiency virus, hepatitis B virus, and hepatitis C virus, following the Occupational Safety and Health Administration's Needlestick Safety and Prevention Act of 2000 [14] [15] [16] . A recent meta-analysis has shown that these devices have reduced the incidence of biohazardous needlestick injuries in health care workers [17] .
Unfortunately, over the past 15 years a growing number of reports have suggested that valved needleless connectors are associated with significantly increased risks of CVC-associated BSI [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] . In most of these reports, the adoption of a new Luer-activated, valved needleless connector by a hospital or home care infusion therapy program-usually replacing a splitseptum connector-has been associated with an abrupt and significant increase in the incidence of nosocomial BSI, particularly CVC-associated BSIs. Multiple manufacturers' valved connectors have been implicated in these reports. In a number of institutions, increased rates of BSI persisted despite intensified efforts to achieve a high level of compliance with infection control practices to prevent CVC-associated BSI, including routinely vigorously disinfecting the membranous septum of the connector before actuation and entry, and BSI rates decreased only after discontinuing use of the new valved connector [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] .
Frequent handling and access of catheter hubs, needless connectors, and injection ports has been shown to put patients at increased risk of CVC-associated primary BSI [18, [20] [21] [22] 28] , presumably because they facilitate entry of microorganisms into the connector and fluid path. In support of this hypothesis, studies have shown a high incidence of biofilm formation on the interior surface of valved connectors that have been used clinically [29] .
Although needleless connectors and injection ports are recognized sites of access for microbial contamination, no national standard exists defining the best and recommended form of antiseptic preparation to prevent microbial entry when the needleless connector or injection port is accessed. Although studies have examined the efficacy of various disinfectants to remove microorganisms from the membranous surface of needleless connectors or injection ports [28, [30] [31] [32] , there have been no randomized clinical trials that have prospectively examined the efficacy of various approaches to disinfection of connectors for prevention of CVC-related BSI. Most importantly, numerous studies have shown that if there is significant contamination of the membranous septum prior to actuation, conventional disinfection may fail to prevent entry of microorganisms [28, [30] [31] [32] [33] [34] [35] [36] . It seems clear that there is an urgent need to develop new technologies that can implicitly reduce the risk of contamination of needleless connectors and associated BSI. We report in vitro studies of a novel antimicrobial luer-activated connector, with a nanoparticle-silver coating of the entire surface, to ascertain its capacity to resist internal fluid contamination and biofilm formation and potential to confer protection against catheterassociated BSI.
METHODS
The novel antimicrobial needleless connector. The novel antimicrobial connector evaluated in this study (V-Link; Baxter Healthcare) is an adaptation of the company's nonmedicated single-use, disposable, luer-activated, valved connector constructed of polycarbonate (Clearlink; Baxter Healthcare), which is designed to connect an administration set or extension set to a vascular catheter and provide needleless access for administration of fluid or withdrawal of blood specimens. However, with the exception of the silicone membranous septum, the entire surface of the antimicrobial connector (Figure 1 ), including the entirety of the internal fluid path and the external casing, has a novel nanoparticle silver coating (V-Link with VitalShield; Baxter Healthcare) to prevent introduced contamination and internal biofilm formation within the device, with the goal of reducing the risk of catheter-associated BSI. The device is not intended to be used as a treatment for established catheter-related BSI.
Study 1: Antimicrobial efficacy, 24-hour challenge. This study was designed to test the capacity of the antimicrobial device to resist contamination of the fluid path, by killing high concentrations of microorganisms present in the fluid path, when tested immediately after removal from the sterile package. Sterile control nonmedicated connectors and antimicrobial connectors were actuated (the administration set was attached to the device, penetrating the membranous septum, triggering the internal valve as the luer connection is completed) and flushed with sterile saline, then filled with ∼ cfu/mL of 5 1 ϫ 10 test microorganisms in bacteriologic media containing 0.1% neopeptone, 0.25% glucose, and 1% bovine serum. After incubation for 24 h, the number of remaining viable microorganisms was quantified and compared with the final concentration in control connectors. Bacteriologic media containing large quantities of protein was employed to provide a worstcase challenge to the device, similar to what might be encountered in clinical use with total parenteral nutrition admixtures or blood, because ionic silver binds to thiol residues, quenching its antibacterial activity [37] .
Tests were performed with suspensions of pure cultures of 6 recent clinical isolates of each of the following microorganisms: Staphylococcus epidermidis, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, Enterobacter cloacae, Pseudomonas aeruginosa, and Candida albicans. All devices to be tested were sterilized and flushed with sterile saline prior to inoculation. The internal fluid path of each device was challenged by aseptically infusing ∼2 mL of the microbial suspension through the device with a syringe to ensure that the entire 0.25-mL fluid-path volume was exposed. After the inoc- ulum was instilled, the syringe was removed and the device was oriented top end down and transferred to a sealed container with residual moisture to prevent evaporation. The device was incubated at 37ЊC for 24 h, using the bacteriologic incubation temperature rather than room temperature (25ЊC) to provide an even greater microbial challenge to the device. After incubation, the connectors were flushed with 2.5 mL of sterile saline containing Tween 20 and sodium thioglycolate to neutralize any remaining ionic silver [37] . The recovered fluid was then cultured quantitatively by plating serial 10-fold dilutions on trypticase soy agar plates in triplicate, which were incubated at 37ЊC in a temperature-controlled incubator for 48 h, after which the number of surviving microorganisms was enumerated.
Study 2: Antimicrobial efficacy, 96-hour challenge. This study was designed to assess the persistence of surface antimicrobial activity on the interior of the device after exposure to stresses intended to simulate 96 h of continuous heavy clinical use. This was achieved via repeated chemical disinfection of the membranous surface with isopropyl alcohol, multiple actuations and prolonged continuous infusion of intravenous fluid through the connector. After exposing the test connectors to repeated actuations and continuous infusion with normal saline for 96 h, connectors were inoculated with the same 6 test microorganisms in bacteriologic media, incubated and sampled using the same protocol as in Study 1.
Study 3:
Clinical simulation trial with assessment biofilm formation. This study was intended to simulate clinical use of the test connectors and to assess their capacity to resist contamination of the fluid path and internal biofilm formation, despite heavy contamination of the membranous portion of the connector at the time of actuation and initiation of continuous flow of intravenous fluid for 72 h. As depicted in Figure  2 , the membranous surface of each test connector was disinfected with 70% isopropyl alcohol, which was allowed to dry, after which it was inoculated with ∼ cfu/mL of E. cloacae 3 1 ϫ 10 (ATCC 2355) suspended in lactated Ringer's with 5% dextrose solution with 1% fetal bovine serum and again allowed to dry. The connector was then actuated with the male Luer adapter of a Continu-Flo infusion set (Baxter Healthcare), which was connected to a 1-liter bag of 5% dextrose-in-lactated Ringer's solution (Baxter Healthcare) containing 1% trypticase soy broth. Fluid was infused at 25ЊC at a rate of 0.5 mL/min for 72 h. Aliquots of infusate from the distal end of an extension tubing connected to the outflow portion of the connector, which were immediately frozen until culturing, were collected at baseline, during hours 1-5, and after 24, 48, and 72 h. Concentrations of viable E. cloacae in each aliquot were determined by plating and culturing serial dilutions in triplicate.
For ascertaining biofilm formation, the exterior surface of the connector was disinfected with sterile gauze saturated with a 1:10 dilution of commercial bleach, which was then inactivated with sterile 5% sodium thiosulfate. The connectors were then cut in half longitudinally with a sterilized pipecutter (Spear and Jackson). Both halves were immersed in a container of sterile 0.9% saline and rinsed by gentle agitation. One half was placed in a tube with 10 mL of a fixing solution of 2% glutaraldehyde in 1N cacodylate buffer and refrigerated prior to processing for scanning electron microscopy.
When processing for scanning electron microscopy, samples were purged of glutaraldehyde by rinsing with 0.1 mol/L cacodylate buffer solution, after which they were dehydrated by serial exposure to 25%, 35%, 50%, 70%, 80%, 90%, and 95% ethanol for 10 min each, followed by a dehydration step with 200-proof ethanol, twice, for 20 min. The samples were then solidified by serial exposure to 2:1, 1:1, and 1:2 ethanol:hexamethyldisilazane baths, each for 15 min, followed by a 100% hexamethyldisilazane solidification 3 times, each for 15 min. The samples were then allowed to dry at room temperature overnight, after which they were mounted on aluminum supports, affixed with carbon tape, and the surfaces sputter-coated with palladium. They were then examined by scanning electron microscopy.
The approximate number of microorganisms present in the biofilm was quantified by processing the other half of the bivalved device by placing it in a 50-mL centrifuge tube containing 10 mL of sterile saline with 0.01% Tween 80 and sodium thioglycolate and vortexing vigorously 3 times, each for 1 minute, then sonicating for 3 min. Ten-fold dilutions of the solution were plated and cultured in triplicate.
RESULTS

Study 1: Antimicrobial efficacy, 24-hour challenge.
With all of the control devices tested immediately after removal from the package, contamination of the contained fluid increased to ∼ cfu/mL by 24 h. The antimicrobial device showed a 7 1 ϫ 10 powerful capacity to rapidly kill microorganisms within the intraluminal fluid path. With 5 of the 6 species tested, there was a 5.23-6.80 mean log 10 reduction (199.999%) compared with controls; with C. albicans, there was a 99.9% reduction (Figure 3) . Study 2: Antimicrobial efficacy, 96-hour challenge. In this experiment, despite heavy manipulation and continuous infusion of normal saline for 96 h before instilling the inoculum and incubating for 24 h, the antimicrobial connectors showed durable capacity to rapidly kill the initial inoculum and prevent growth of microorganisms within the intraluminal fluid path. There was a 3.0-6.8 mean log 10 reduction (99.9%-99.9999% reduction), compared with control nonmedicated connectors (Figure 4) , which again demonstrated a rapid increase in contamination to ∼ cfu/mL. 7 1 ϫ 10 Study 3: Clinical simulation trial with assessment biofilm formation. In all 36 trials with control connectors, large numbers of microorganisms were detected in efferent infusate (Figure 5) . Approximately cfu/mL were detected at 1 h, 2 1 ϫ 10 at 48 h, and at 72 h. Commensurate biofilm 3 5 1 ϫ 10 1 ϫ 10 formation was present at each of these sampling periods (Figure 6) .
In contrast, only 1-3 cfu/mL were detected at 1 h in 5 of 36 trials with antimicrobial connectors, with no detectable fluid Figure 6 . Scanning electron microscopy of connectors after 72 h of exposure in Study 3 (magnification, ϫ10,000) . The control connectors all had a heavy biofilm observed on scanning electron microscopy, with ∼ cfu recovered per connector, whereas none of the antimicrobial connectors 4 1 ϫ 10 demonstrated any biofilm formation on scanning electron microscopy, and all were sterile in culture.
contamination thereafter ( Figure 5 ). There was no biofilm formation whatsoever detected at any of the sampling periods ( Figure 6 ).
DISCUSSION
Numerous epidemics of nosocomial BSI have been traced to the entry of microorganisms through the lumen of the catheter into the patient's bloodstream, most often in contaminated infusate [1] . However, in a growing number of recent outbreaks, needleless valved connectors for CVCs appear to have become extrinsically contaminated by microorganisms which traversed the septal membrane to colonize the internal surface of the connector, presumably resulting in the formation of a biofilm and shedding of microorganisms into the fluid path [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] . Unfortunately, there have not been adequate studies to assess the relative importance of this mechanism of microbial access as a cause of endemic CVC-related BSI. However, Donlan et al [29] found that up to 63% of randomly sampled needleless connectors in clinical use demonstrated viable biofilms.
The in vitro simulation studies we report demonstrate unequivocally the capacity of microorganisms to gain access to the interior of the connector at the time of actuation or, later, during continuous use to rapidly form a luxurious biofilm which, within 24-48 h, begins to shed into the fluid path downstream ( Figure 5 ) and ultimately into the bloodstream of the patient receiving the infusion. Moreover, studies have shown that if there is significant contamination of the membranous septum prior to actuation, conventional disinfection often fails to prevent entry of microorganisms [28, [30] [31] [32] [33] [34] [35] [36] .
With the recent reports that many hospitals in the United States have experienced increased rates of nosocomial BSI that appear to be related to commercial needless connectors that are being used universally, particularly with CVCs or peripherally-inserted CVCs [1827], it seems clear that there is an urgent need for the development of novel technologies to reduce the risk of in-use contamination of connectors which can cause catheter-related BSI. It is noteworthy that the first technologic approaches to preventing contamination of CVC-administration set-catheter connections by use of a povidoneiodine "shield" [33] or a novel antiseptic-containing connector showed greatly reduced rates of CVC-associated BSI in trials in Europe, where there was a very high baseline incidence of CVC-associated infection [34] [35] [36] .
The novel nanosilver-impregnated polycarbonate valved needleless connector we have studied was recently approved by the Food and Drug Administration and is now in use in many hospitals in the United States. The nanosilver particles are stably imbedded in the polycarbonate matrix and release minute quantities of bactericidal ionic silver off the surface into the fluid path. Simulation studies have shown that the total amount of ionic silver eluted into the fluid pathway with continuous infusion-and infused into the patient-is ∼0.80 mg per day, resulting in an incremental increase in the blood level of silver of ∼0.05 ng/mL. This is far below levels of silver exposure considered to pose a risk to human health; silver concentrations in drinking water up to 100 mg/L are considered to be safe by the United States Environmental Protection Agency, and mean blood silver levels in unexposed healthy humans range from 0.2-5 ng/mL [38, 39] . The amounts of silver entering the bloodstreams of patients exposed to this nanosilver-impregnated connector are magnitudes less than occurs in patients treated with topical silver sulfadiazine or silver dressings, where blood levels of silver can reach hundreds of micrograms per milliliter [38] . Most absorbed silver is excreted in the feces and urine.
Our in vitro studies (Studies 1 and 2), which posed microbial challenges to the antimicrobial connector far beyond those likely be encountered in clinical practice and used incubation temperatures of 37ЊC and high concentrations of protein in nutrient media, similar to what would be encountered with infusion of warmed blood or protein-containing total parenteral nutrition admixtures, demonstrate that incorporation of the nanoparticle-silver coating onto the interior surfaces of the polycarbonate connector rapidly kills microorganisms in the fluid path and prevents biofilm formation, even in the presence of high concentrations of protein that can sequester silver and neutralize its antibacterial activity [37] . With 5 of the 6 species tested, there was a 5.23-6.80 mean log 10 reduction (199.999%), compared with controls (Figure 3) , and with C. albicans, there was a 99.9% reduction. Stressing connectors for 96 h with repeated actuations and a continuous infusion had no material effect on the capacity of the connectors to rapidly kill microorganisms suspended in the internal fluid path (Figure 4) . Even more importantly, in Study 3, which simulated clinical use by exposing connectors to heavy contamination and continuous flow for 72 h, there was near-total prevention of downstream fluid contamination ( Figure 5 ) and complete suppression of biofilm formation ( Figure 6 ).
In conclusion, this promising novel technology deserves to be evaluated in prospective, adequately powered, randomized clinical trials with catheter-associated BSI as the primary outcome measure [40] , to ascertain its capacity to prevent bacteremia deriving from in-use contamination of needless connectors.
